| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_079a5b3eecbeb0e5fcc2e9b817b28c97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2017-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b823e5ba397fd8686ebd8ad0adb885dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9391435ebdf8c7da1c80fcf6f77ad2a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a9c1b9f30c9d10829c3a50ccafa30e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ea7544caf07b60687cf91e12f133701 |
| publicationDate |
2018-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3327015-A1 |
| titleOfInvention |
Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin- 3'-oxime as active ingredient |
| abstract |
A breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as cyclin-dependent kinase (CDK) inhibitor, wherein said breast cancer is triple negative breast cancer (TNBC) and/or an estrogen receptor (ER) positive breast cancer including the tamoxifen-resistant estrogen receptor (ER) positive breast cancer has been disclosed. |
| priorityDate |
2016-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |